Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12526593 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTTTP53 | |
| SCHEMBL14334288 | 0.94 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTTTP53 | |
| SCHEMBL30841381 | 0.94 | USP30 (0.51) | SMN1; SMN2NPC1RAB9AHTTTP53 | |
| SCHEMBL14334908 | 0.92 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AHTTTP53 | |
| SCHEMBL23163823 | 0.91 | PARP1 (0.47) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL28974757 | 0.91 | PARP1 (0.47) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL18756737 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTTP53 | |
| SCHEMBL14334656 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL31461542 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL310136 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332266-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4615850-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BeiGene Switzerland GmbH (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-17 | — | — | US | disclosed |
| EP-4444724-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BeiGene Switzerland GmbH (CH) | 2024-10-16 | — | — | EP | disclosed |
| CN-118488958-A | Compounds for degrading EGFR kinase | 百济神州有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024099395-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (KY) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024099402-A1 | INTERMEDIATES AND PROCESS OF COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE (BEIJING) CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024099400-A1 | INTERMEDIATES AND PROCESS OF COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE (BEIJING) CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332266-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4558/4885NPC1 3259/4885RAB9A 1739/4885 |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | SMN1; SMN2 4558/4885NPC1 3259/4885RAB9A 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.